rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GHRS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Guggenheim raises GH Research stock price target to $46 on pivotal trial progress
      14h agoInvesting.comGHRS
      Depression Drug Opportunity Has Analysts Buying the GHRS Dip - GH Research (NASDAQ:GHRS)
      Nov 16BenzingaGHRS
      Stifel reiterates GH Research stock rating on FDA alignment
      Nov 13Investing.comGHRS
      GH Research names Vanina Popova as chief development officer
      Nov 13Investing.comGHRS
      GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update

      Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support going from 3 → 1 doses per treatment visitTRD pivotal program — positive initial feedback from FDA, End-of-Phase 2 meeting expected in Q1 2027, initiation shortly afterPPD pivotal program — initiation targeted for H2 2027Vanina Popova, MD, appointed Chief Development Officer — Formerly Clinical Development at J&J, lead author of pivotal Spravato® trial publicationCash, cash equivalents and marketabl

      Nov 13Yahoo FinanceGHRS
      GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer

      Dr. Popova will lead the clinical development of GH001 as the company advances toward pivotal programs in TRD and PPDBrings more than 20 years of global pharmaceutical R&D experience at Johnson & Johnson across clinical operations, clinical development, regulatory strategy, and neuroscience portfolio leadershipClinical lead in the Spravato® (esketamine) program, where she led TRANSFORM-2, one of the pivotal Phase 3 trials that supported its approval in TRD, and was lead author of the trial publi

      Nov 13Yahoo FinanceGHRS
      GH Research (GHRS) Stock Looks Fully Priced As Book Value Questions Linger

      GH Research has delivered a powerful share price run in recent years, which puts fresh attention on whether the current market value lines up with the company’s book value. With the stock recently closing at US$20.86, the question is how much of that price is anchored in the balance sheet and how much reflects expectations that sit beyond it. Over the past 3 years, GH Research has gained about 152.5%. This places a lot of weight on whether its book value can support that kind of share price...

      Nov 1Yahoo FinanceGHRS
      GH Research Remains Undervalued Ahead Of Pivotal Phase III Program (NASDAQ:GHRS)
      Oct 23Seeking AlphaGHRS
      GH Research (GHRS) Stock May Look Stretched As Book Value Trails Price
      Oct 18Yahoo FinanceGHRS
      GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities

      Initiate coverage on GH Research: Buy rating as FDA hold lifts for GH001 TRD, Phase 3 in 2026. Click for more on GHRS stock.

      Sep 20Seeking AlphaGHRS
      Analysts Offer Insights on Healthcare Companies: GH Research (GHRS), Evaxion Biotech (EVAX) and Ibio (IBIO)

      Detailed price information for Ibio Inc (IBIO-Q) from The Globe and Mail including charting and trades.

      Sep 1The Globe and MailEVAXGHRS
      Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight

      Recently published Postpartum Depression Market Insights report includes a comprehensive understanding of current treatment practices, postpartum depression emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

      Aug 25Yahoo FinanceGHRSLPCN

      This is the newest page. Registered accounts read further back.